Opus Genetics (IRD) had the highest return between January 22, 2017 and March 31, 2017 by a small-cap US stock, returning 200%.
| ASSET | DATE | % RETURN |
|---|---|---|
Opus Genetics (IRD) | 1/22/2017 - 3/31/2017 | 200% |
Galectin Therapeutics (GALT) | 1/22/2017 - 3/31/2017 | 123.3% |
Quantum Computing (QUBT) | 1/22/2017 - 3/31/2017 | 100% |
Syndax Pharmaceuticals (SNDX) | 1/22/2017 - 3/31/2017 | 97.69% |
Nektar Therapeutics (NKTR) | 1/22/2017 - 3/31/2017 | 94.77% |
Verastem (VSTM) | 1/22/2017 - 3/31/2017 | 84.82% |
AnaptysBio (ANAB) | 1/22/2017 - 3/31/2017 | 73.44% |
Sanara Medtech (SMTI) | 1/22/2017 - 3/31/2017 | 68.68% |
DiaMedica Therapeutics (DMAC) | 1/22/2017 - 3/31/2017 | 68.04% |
Omeros (OMER) | 1/22/2017 - 3/31/2017 | 64.53% |
Fennec Pharmaceuticals (FENC) | 1/22/2017 - 3/31/2017 | 59.22% |
Tronox (TROX) | 1/22/2017 - 3/31/2017 | 57.01% |
Chemours (CC) | 1/22/2017 - 3/31/2017 | 56.64% |
Hello (MOMO) | 1/22/2017 - 3/31/2017 | 56.07% |
Cronos (CRON) | 1/22/2017 - 3/31/2017 | 53.71% |
Zevra Therapeutics (ZVRA) | 1/22/2017 - 3/31/2017 | 53.13% |
Rigel Pharmaceuticals (RIGL) | 1/22/2017 - 3/31/2017 | 52.53% |
Cypherpunk Technologies (CYPH) | 1/22/2017 - 3/31/2017 | 50.25% |
CytomX Therapeutics (CTMX) | 1/22/2017 - 3/31/2017 | 50.17% |
Nutex Health (NUTX) | 1/22/2017 - 3/31/2017 | 50% |
Harrow Health (HROW) | 1/22/2017 - 3/31/2017 | 50% |
Altimmune (ALT) | 1/22/2017 - 3/31/2017 | 50% |
GeoPark (GPRK) | 1/22/2017 - 3/31/2017 | 49.27% |
LightPath Technologies (LPTH) | 1/22/2017 - 3/31/2017 | 48.91% |
Clear Channel Outdoor (CCO) | 1/22/2017 - 3/31/2017 | 48.03% |
Small-cap stocks are treated as having a market cap between $300M and $2B.